Select Publications
Conference Abstracts
2024, 'A minority of women of childbearing potential are tested for pregnancy before chemoimmunotherapy: an Australian cancer centre experience', in Internal Medicine Journal, Vol. 54, pp. 750 - 754, http://dx.doi.org/10.1111/imj.16287
,2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9
,2022, 'Role of Endomyocardial Biopsy and Mass Spectrometry for Precision in Cardiac Amyloid Subtyping: A Case Series', in Heart, Lung and Circulation, Elsevier BV, Vol. 31, pp. S99 - S100, http://dx.doi.org/10.1016/j.hlc.2022.06.123
,2021, 'A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS8055
,2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', in Blood, American Society of Hematology, Vol. 136, pp. 11 - 12, http://dx.doi.org/10.1182/blood-2020-138991
,2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', in Blood, American Society of Hematology, Vol. 136, pp. 42 - 43, http://dx.doi.org/10.1182/blood-2020-139269
,